Uso ottimale del docetaxel nella chemioterapia adiuvante delle pazienti con carcinoma mammario HER2-negativo

Translated title of the contribution: Optimal role of docetaxel in adjuvant chemotherapy for early stage HER2-negative breast cancer

S. I S Fattoruso, S. Rossi, P. Vici, F. Di Filippo, C. Botti, L. Di Lauro, P. Foggi, E. Saracca, F. R. Ferranti, P. Visca, M. Lopez

Research output: Contribution to journalArticle

Abstract

The fundamental imperative of adjuvant treatment of early breast cancer is to improve long-term survival and minimize toxicity. The inclusion of docetaxel in adjuvant chemotherapy regimens has improved patient survival in comparison to anthracycline-containing regimens, even if the incidence of acute side effects has increased in some studies. However, late or persistent toxic effects are becoming more important due to an increasing proportion of patients remaining disease free after treatment for early breast cancer. Several studies have recently reported that docetaxel-containing regimens without anthracyclines are equally active, and have no apparent cardiotoxicity. At present, docetaxel-based combinations represent an appropriate choice in the adjuvant treatment of HER2-negative breast cancer, and several studies are ongoing aiming at a better evaluation of the efficacy of this agent in order to optimize its role.

Translated title of the contributionOptimal role of docetaxel in adjuvant chemotherapy for early stage HER2-negative breast cancer
Original languageItalian
Pages (from-to)443-447
Number of pages5
JournalClinica Terapeutica
Volume159
Issue number6
Publication statusPublished - Nov 2008

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Optimal role of docetaxel in adjuvant chemotherapy for early stage HER2-negative breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Fattoruso, S. I. S., Rossi, S., Vici, P., Di Filippo, F., Botti, C., Di Lauro, L., Foggi, P., Saracca, E., Ferranti, F. R., Visca, P., & Lopez, M. (2008). Uso ottimale del docetaxel nella chemioterapia adiuvante delle pazienti con carcinoma mammario HER2-negativo. Clinica Terapeutica, 159(6), 443-447.